Restera
5 known investors
Restera develops neurostimulation and sleep therapy medical devices, bringing over 75 years of combined expertise in these areas with 100+ FDA approvals. The company serves patients requiring sleep and neurological treatment solutions.
Also known as Restera Sleep
Founders & leadership
Investors · 5
Company profile
researched Aug 2026Restera is a clinical-stage medical technology company developing a treatment for obstructive sleep apnea (OSA) based on a miniature neurostimulation implant. The device is designed to be placed through a needle in a short outpatient procedure, without an incision or visible scarring, and to deliver stimulation during sleep that opens the airway and improves breathing.
The company frames its development work around three areas: novel neural targets, including a new region of the hypoglossal nerve (HGN) and the ansa cervicalis (AC) nerve; incision-free delivery combining ultrasound guidance with needle injection; and patented tools and methods intended to enable rapid, accurate device placement in an outpatient setting. Restera states that early clinical results indicate therapeutic benefit from each of the targeted nerves and that additional clinical work is underway.
Restera reports assembling a team of clinicians, engineers and investors alongside partnerships with research institutions. Its board of directors is described as bringing medical technology and life sciences operating, clinical and financial experience, and its scientific advisory board includes experts affiliated with the University of Pennsylvania, Vanderbilt University, Stanford University, Flinders University and Monash University.
Traction
The company reports six clinical studies encompassing 68 subjects, 54 patents and 15 peer-reviewed publications, and states that further clinical work is in progress.
▸Full profile — market position, technology, go-to-market, risks & controversies
Market position
Restera positions its implant against continuous positive airway pressure (CPAP), which the company describes as the therapy used by 85% of diagnosed sleep apnea patients but with nearly half of users non-compliant due to devices being cumbersome, loud, uncomfortable and intrusive. The company characterizes its approach as a first-of-its-kind sleep apnea treatment and cites an advisor describing a level of airflow restoration not yet seen with other stimulation approaches.
Technology
The core technology is a miniature implant that applies established neurostimulation methods to targeted nerves involved in airway patency. Restera cites novel neural targets, including a new area of the hypoglossal nerve and the ansa cervicalis nerve, and combines ultrasound guidance with needle-based injection so that the implant can be delivered without an incision. Proprietary, patented placement tools and methods are intended to allow accurate positioning within minutes. The company reports 54 patents and 15 peer-reviewed publications.
Go-to-market
Patients with obstructive sleep apnea, a population the company cites at approximately one billion sufferers worldwide, of whom about 80% remain undiagnosed. Therapy would be delivered by clinicians in outpatient settings.
Risks & controversies
The company is clinical-stage, with its implant still in development and not described as approved or commercially available; adoption depends on the outcome of ongoing and future clinical work.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
In the news
▸Research sources · 1
primary sources listed
- Resteraresterasleep.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Restera do?
- Clinical-stage medical device company developing a needle-injected neurostimulation implant for obstructive sleep apnea.
- Who are Restera's investors?
- Restera's investors include Supermoon Capital, Aphelion Capital, Forepont Capital Partners, Dns Capital, GreatPoint Ventures.